It is usually prescribed at 250 mg twice a day [7]. Two initial phase I clinical trials leading to the approval of crizotinib prescribed the drug at 250 mg twice a day to 255 ALK-positive patients, who had metastatic or locally advanced NSCLC. Here, ALK is linked to non-small cell lung carcinoma.